product name Vinpocetine
Description: Vinpocetine (also known as RGH-4405) is a potent and selective voltage-sensitive sodium channel blocker for the treatment of stroke, vascular dementia and Alzheimers disease. Vinpocetine has been reported to have a selective and noncompetitive inhibition of Ca2+ PDE and thus regulate cyclic GMP levels in smooth muscle. In addition, vinpocetine has been revealed to inhibit the activities of three resolvable PDE in the cytosol of rat aorta with Ki values of 14±2μM, >1000μM and >1000μM for Ca2+ PDE(+)CaM, cGMP PDE and cAMP PDE, respectively.
References: Brain Res Bull. 2000 Oct;53(3):245-54; Br J Pharmacol. 1989 Nov;98(3):725-34.
350.45
Formula
C22H26N2O2
CAS No.
42971-09-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (8.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
RGH-4405
other peoduct :
| In Vitro |
In vitro activity: Vinpocetine has been reported to have a selective and noncompetitive inhibition of Ca2+ PDE and thus regulate cyclic GMP levels in smooth muscle. In addition, vinpocetine has been revealed to inhibit the activities of three resolvable PDE in the cytosol of rat aorta with Ki values of 14±2μM, >1000μM and >1000μM for Ca2+ PDE(+)CaM, cGMP PDE and cAMP PDE, respectively. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Vinpocetine has shown the potent inhibition of 5-HT-induced contractions in endothelium-intact rat aorta with an EC50 value of 1μM. |
| Animal model | |
| Formulation & Dosage | |
| References | Br J Pharmacol. 1989 Nov;98(3):725-34. |
